Novel Therapeutics Screening
Research type
Research Study
Full title
Supporting the discovery and development of novel therapeutics utilising primary cells and tissues as model systems
IRAS ID
343167
Contact name
Hayley Gooding
Contact email
Sponsor organisation
Concept Life Sciences
Duration of Study in the UK
5 years, 0 months, 0 days
Research summary
Concept Life Sciences (CLS) is an innovative contract research organization (CRO). The Edinburgh site is focused on Translational Biology and was originally formed as a spin-out from the University of Edinburgh before being acquired by CLS in 2017. CLS were subsequently acquired by the precision instrument company, Spectris, in 2017, and merged with sister company Malvern Panalytical in 2021. In March 2023, CLS underwent a divestment and are now owned by Private Equity group, Limerston Capital.
CLS Edinburgh provide highly specialized preclinical services with a focus on Immuno-oncology, Neuroscience, Autoimmune Disease and Immunology. CLS Edinburgh currently offer a range of services to support drug discovery and development including various in vitro and in vivo animal models in addition to a range of human immune cell assays. These can be used to screen compounds to identify promising new therapies and to characterise potential new targets.
REC name
London - Fulham Research Ethics Committee
REC reference
24/PR/0642
Date of REC Opinion
10 Jun 2024
REC opinion
Further Information Favourable Opinion